The Middle East and Africa late-stage chronic kidney disease drugs market is expected to reach US$ 294.07 million by 2027 from US$ 143.27 million in 2019; it is estimated to grow at a CAGR of 9.6% from 2020 to 2027.
The high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policies for the late-stage chronic kidney disease treatments are among the key factors driving the market growth in this region. However, delay in the diagnosis of chronic kidney diseases hampers the market growth.
The late-stage renal disease is characterized by the loss of kidney’s ability to filter waste and excess fluid from blood, leadings to waste accumulation in the body. Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people in the world. As perthe Lancet Global Health report published in December 2019,the overall prevalence of chronic kidney disease in South Africa was 15.8%, and the number of people opting for the treatment of the same is expected to increase with the mounting awareness regarding this condition. Moreover, the rising prevalence of high blood pressure and diabetes is a major cause of the progression of end-stage kidney disease (ESKD). These factors are expected to enhance market growth during the forecast period. Also, various strategies proposed by the World Health Organisation (WHO) to support policymakers in developing suitable policies, encompassing the vital medicine list concept and the universal health coverage (UHC) approach would boost the market growth in the coming years.
The COVID-19 pandemic has negatively impacted Middle East and Africa late-stage chronic kidney disease drugs market. Elderly people and kidney disease patients seem to be at higher risk for more serious COVID-19 illness. However, Nephrology societies have made suggestions and provided guidelines to prevent COVID-19 transmission in dialysis facilities and to provide emergency services for patients. Therefore, the late-stage chronic kidney disease drugs market is expected to regain traction in the coming months.
Based on product type, Middle East and Africalate-stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the largest market share in 2019, and it is expected to register the highest CAGR in the market during 2020–2027.
The Middle East and Africalate-stage chronic kidney disease drugs market, by indication, is segmented into late-stage chronic kidney disease induced hyperparathyroidism, late-stage chronic kidney disease induced hyperphosphatemia, and late-stage chronic kidney disease induced hyperkalemia. The late-stage chronic kidney disease induced hyperparathyroidism segment held the largest share of the market in 2019, and it is anticipated to register the highest CAGR during the forecast period.
On the basis of distribution channel, the Middle East and Africalate-stage chronic kidney disease drugs market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment held the largest share of the market in 2019; however, the online pharmacy is estimated to register the highest CAGR in the market from 2020 to 2027.
A few of the primary and secondary sources associated with report on the Middle East and Africalate-stage chronic kidney disease drugs market are the National Center for Biotechnology Information (NCBI), Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH).